FIGURE 1.

ERK1/2 inhibition increases levels of PGC-1α and downstream targets of MB mRNA. A, immunoblotting analysis of phosphorylated ERK1/2 (p-ERK1/2) in RPTC in response to increasing concentrations of trametinib at 4 h and increasing time of exposure to 10 nm trametinib. Veh, vehicle; MW, molecular weight. B–E, mRNA expression of PGC-1α, TFAM, NDUFS1, and NRF1 at 1, 4, and 24 h after treatment with 10 nm trametinib. Data are represented as mean ± S.E., n ≥ 5. Different superscripts indicate statistically significant differences (p < 0.05).